GlobeImmune, which is developing therapeutic drugs for pancreatic cancer and hepatitis B and C, lowered the proposed deal size for its upcoming IPO on Monday. The Louisville, CO-based company now plans to raise $15 million by offering 1.0 million shares at $15 per share. The company had initially filed to offer 2.2 million shares at a range of $15 to $17 but dropped the shares offered to 1.6 million in late May. At the revised price and share count, GlobeImmune would raise 57% fewer proceeds than originally planned.
GlobeImmune, which was founded in 1995 and booked $22 million in collaboration and milestone revenue for the 12 months ended March 31, 2014, plans to list on the NASDAQ under the symbol GBIM. Aegis Capital is the sole bookrunner on the deal. It is expected to price during the week of June 30, 2014.
